New York, Feb 8, 2026, 10:26 EST — The market has closed.
- JNJ climbed 0.93% to finish at $239.99, but edged down 0.12% in after-hours, settling at $239.70
- Beasley Allen has been tossed from the consolidated New Jersey state talc cases by an appeals court, but the plaintiffs’ firm says it’s appealing the decision.
- J&J has put out fresh pilot data on its experimental AFib platform, just as investors brace for a packed week of U.S. data releases.
Johnson & Johnson closed out Friday’s session at $239.99, gaining 0.93%, before edging down 0.12% to $239.70 in after-hours trading. Shares never strayed far from the 52-week high, staying inside a tight $237.98 to $240.93 range.
Investors found themselves juggling two recurring themes: more developments in the ongoing talc lawsuits, plus newly released MedTech numbers related to the heart-rhythm devices segment. The two issues differ in scale, but either one can quickly sway sentiment in a stock that’s typically seen as a reliable compounder.
Late-week trading tilted risk-on. The Dow punched through 50,000 for the first time Friday. S&P 500 and Nasdaq both surged, powered by chip stocks rallying on bets for increased AI infrastructure outlays. J&J gained as well, though the move was minor compared to the rest of the board.
An appeals court in New Jersey has blocked plaintiffs’ firm Beasley Allen from taking part in a consolidated batch of state lawsuits over alleged cancer links to talc baby powder. The judges pointed to improper coordination between Beasley Allen and a lawyer who’d previously worked for J&J on the same cases. Beasley Allen plans to challenge the ruling. “Anything less would reward unethical behavior and undermine the fairness every litigant is entitled to expect,” said Erik Haas, J&J’s global litigation chief. This order only hits the New Jersey state proceedings; a related bid targeting federal cases—where most of J&J’s talc exposure sits—is still outstanding. Reuters
J&J reported that in its OMNY-AF pilot, 90% of the 30 patients hit the study’s main effectiveness goal at 12 months, and none experienced procedure-related adverse events. The platform, OMNYPULSE, remains investigational and isn’t cleared anywhere yet, the company noted. Updates on its VARIPULSE platform were also shared, with new data indicating that workflow tweaks correlated with a low rate of neurovascular events in real-world use. “Pulse field ablation technologies should be individually evaluated for safety and reproducibility in atrial fibrillation ablation,” said Gregory Michaud, chief medical and scientific officer for electrophysiology in MedTech. JNJ.com
Pulsed field ablation works by sending bursts of electricity to disrupt specific heart tissue—distinct from the heat-focused techniques that still dominate many ablation procedures. Competition in the space is intense. Medtech heavyweights like Boston Scientific and Medtronic have ramped up efforts around rhythm-management tools, so for any fresh platform, safety and reliability become the first hurdles.
Monday brings a test: will the talc decision actually shift settlement leverage, or just recede into legal noise again? Over in MedTech, the update is more straightforward, though nobody expects early pilot data to resolve the persistent questions over uptake or regulatory timing.
Still, things could shift quickly. If Beasley Allen’s appeal gains traction, it might soften the blow from the New Jersey ruling. And there’s always the chance a different federal court could rule to disqualify—bad news for J&J either way, with the talc cases potentially making headlines again. Devices? Early data and splashy conference reveals often seem neater than what emerges once they’re actually in use.
Macro forces could end up moving the stock more than any headline for now. A spike in bond yields or a sudden shift in risk appetite back toward growth, and investors might dump big healthcare names fast—even those with solid product portfolios.
Traders now look to the U.S. data slate. The Bureau of Labor Statistics will drop the January jobs numbers Wednesday, Feb. 11, at 8:30 a.m. ET, followed by the January CPI two days later, same time. Both reports have the potential to jolt rate-cut positioning and shift sector allocations in the days ahead.
